Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Int J Cancer. 2010 Nov 15;127(10):2292-9. doi: 10.1002/ijc.25256.
Distant metastasis is the major cause of death in colorectal cancer (CRC) patients. To identify genes influencing the prognosis of patients with CRC, we compared gene expression in primary tumors with and without distant metastasis using an oligonucleotide microarray. We also examined the expression of the candidate gene in 100 CRC patients by quantitative real-time reverse transcription PCR and studied the relationship between its expression and the prognosis of patients with CRC. As a result, we identified MUC12 as a candidate gene involved in metastasis processes by microarray analysis. Quantitative real-time reverse transcription PCR showed that MUC12 expression was significantly lower in cancer tissues than in adjacent normal tissues (p < 0.001). In Stages II and III CRC, patients with low expression showed worse disease-free survival (p = 0.020). Multivariate analysis disclosed that MUC12 expression status was an independent prognostic factor in Stages II and III CRC (relative risk, 8.236; 95% confidence interval, 1.702-39.849 p = 0.009). Our study revealed the prognostic value of MUC12 expression in CRC patients. Moreover, our result suggests MUC12 expression is a possible candidate gene for assessing postoperative adjuvant therapy for CRC patients.
远处转移是结直肠癌（CRC）患者死亡的主要原因。为了鉴定影响 CRC 患者预后的基因，我们使用寡核苷酸微阵列比较了有远处转移和无远处转移的原发肿瘤中的基因表达。我们还通过定量实时逆转录 PCR 检查了 100 名 CRC 患者的候选基因表达情况，并研究了其表达与 CRC 患者预后之间的关系。结果，我们通过微阵列分析确定 MUC12 是参与转移过程的候选基因。定量实时逆转录 PCR 显示，癌症组织中的 MUC12 表达明显低于相邻正常组织（p < 0.001）。在 II 期和 III 期 CRC 中，低表达的患者无病生存期更差（p = 0.020）。多因素分析显示，MUC12 表达状态是 II 期和 III 期 CRC 的独立预后因素（相对风险，8.236；95%置信区间，1.702-39.849；p = 0.009）。我们的研究揭示了 MUC12 表达在 CRC 患者中的预后价值。此外，我们的结果表明 MUC12 表达是评估 CRC 患者术后辅助治疗的候选基因之一。
